

Practitioner's Docket No: 700157-47577C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Marasco et al.

Application No.: 09/522,727

Filed: 3/10/00

Group No.: 1644

Examiner: J. Roark

For: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,  
AND/OR AMENDMENT PERTAINING THERETO  
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE  
AND/OR AMINO ACID SEQUENCE

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Ronald I. Eisenstein, state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is **mandatory**;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10\*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_ (mandatory)

  
Signature

Date: 7/3/02

Zinna L. Mang  
(type or print name of person certifying)

A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

An Amendment Under 37 C.F.R. § 1.825.

Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.

**STATEMENT THAT "SEQUENCE LISTING"  
AND COMPUTER READABLE COPY ARE THE SAME  
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

The "Sequence Listing" and computer readable copy are the same.

**If any additional extension and/or fee is required, charge Account No. 50-0850.**

  
SIGNATURE OF PRACTITIONER


Reg. No. 30,628

Ronald I. Eisenstein


Tel. No.: (617) 345-6054

NIXON PEABODY LLP  
101 Federal Street

Boston, MA 02110



RECEIVED  
JUL 11 2002  
TECH CENTER 1600/2900



1644

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/522,727C

DATE: 02/21/2002

TIME: 11:13:55

Input Set : A:\#538999 v1 - seqlist.txt

Output Set: N:\CRF3\02212002\I522727C.raw

Does Not Comply  
Corrected Diskette Needed

*pg 1-2*

4 <110> APPLICANT: DANA-FARBER CANCER INSTITUTE, INC.  
5 MARASCO, Wayne  
6 MHASHILKAR, Abner  
8 <120> TITLE OF INVENTION: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS  
10 <130> FILE REFERENCE: 47577 C  
12 <140> CURRENT APPLICATION NUMBER: US/09/522,727C  
13 <141> CURRENT FILING DATE: 2000-03-10  
15 <150> PRIOR APPLICATION NUMBER: 60/059,339  
16 <151> PRIOR FILING DATE: 1997-09-19  
18 <160> NUMBER OF SEQ ID NOS: 56  
20 <170> SOFTWARE: FastSEQ for Windows Version 3.0

ERRORED SEQUENCES

22 <210> SEQ ID NO: 1  
23 <211> LENGTH: *(5) 15 shown*  
24 <212> TYPE: PRT  
25 <213> ORGANISM: human  
27 <400> SEQUENCE: 1  
28 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
E--> 29 1 5 10 15  
690 <210> SEQ ID NO: 54  
691 <211> LENGTH: 277  
692 <212> TYPE: PRT  
693 <213> ORGANISM: human  
695 <400> SEQUENCE: 54  
696 Met Glu His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp  
697 1 5 10 15  
698 Val Leu Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Thr Arg  
699 20 25 30  
700 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
701 35 40 45  
702 Thr Ser His Trp Met Gln Trp Val Arg Gln Arg Pro Gly Gln Gly Leu  
703 50 55 60  
704 Glu Trp Ile Gly Thr Ile Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr  
705 65 70 75 80  
706 Gln Asn Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr  
707 85 90 95  
708 Thr Ala Tyr Leu His Leu Ser Ser Leu Ser Ser Glu Asp Ser Ala Val  
E--> 709 100 105 *110 ← insert*  
710 Tyr Tyr Cys Ala Arg Asp Glu Ile Thr Thr Val Val Pro Arg Gly Phe  
711 115 120 125

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/522,727C

DATE: 02/21/2002

TIME: 11:13:55

Input Set : A:\#538999 v1 - seqlist.txt

Output Set: N:\CRF3\02212002\I522727C.raw

712 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly  
713 130 135 140  
714 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Leu  
715 145 150 155 160  
716 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Asp Thr Ile Thr  
717 165 170 175  
718 Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp Leu Ser Trp Tyr  
719 180 185 190  
720 Gln Gln Lys Pro Gly Asn Ile Pro Gln Leu Leu Ile Tyr Lys Ala Ser  
721 195 200 205  
722 Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly Arg Gly Ser Gly  
723 210 215 220  
724 Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Gly  
725 225 230 235 240  
726 Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Leu Thr Phe Gly Gly  
727 245 250 255  
728 Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser  
729 260 265 270  
730 Glu Lys Asp Glu Leu

Use of n or Xaa has been detected in the Sequence Listing.  
Review the Sequence Listing to insure a corresponding  
explanation is presented in the <220> to <223> fields of  
each sequence using n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/522,727C

DATE: 02/21/2002

TIME: 11:13:56

Input Set : A:\#538999 v1 - seqlist.txt

Output Set: N:\CRF3\02212002\I522727C.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application Number  
L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:29 M:252 E: No. of Seq. differs, <211>LENGTH:Input:5 Found:15 SEQ:1  
L:284 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29  
L:286 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29  
L:526 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:51  
L:526 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51  
L:527 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:51  
L:527 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51  
L:590 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:52  
L:709 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:54